Roger Susi Sells 5,000 Shares of iRadimed (NASDAQ:IRMD) Stock

iRadimed Corporation (NASDAQ:IRMD) CEO Roger Susi sold 5,000 shares of the stock in a transaction dated Monday, April 20th. The shares were sold at an average price of $93.36, for a total value of $466,800.00. Following the completion of the transaction, the chief executive officer directly owned 2,205,000 shares of the company’s stock, valued at $205,858,800. This represents a 0.23% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

iRadimed Price Performance

IRMD traded up $0.96 on Wednesday, reaching $90.14. The company’s stock had a trading volume of 62,414 shares, compared to its average volume of 80,609. The stock has a market cap of $1.15 billion, a price-to-earnings ratio of 51.51 and a beta of 1.11. iRadimed Corporation has a 1 year low of $50.00 and a 1 year high of $107.90. The business’s 50 day moving average is $98.63 and its 200 day moving average is $93.51.

iRadimed (NASDAQ:IRMD) last issued its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $0.54 EPS for the quarter, beating analysts’ consensus estimates of $0.49 by $0.05. The firm had revenue of $22.69 million during the quarter, compared to the consensus estimate of $21.60 million. iRadimed had a return on equity of 23.83% and a net margin of 26.82%.iRadimed has set its Q1 2026 guidance at 0.440-0.480 EPS and its FY 2026 guidance at 2.060-2.210 EPS. As a group, research analysts forecast that iRadimed Corporation will post 1.94 earnings per share for the current fiscal year.

iRadimed Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, March 6th. Shareholders of record on Monday, February 23rd were paid a dividend of $0.20 per share. The ex-dividend date was Monday, February 23rd. This is an increase from iRadimed’s previous quarterly dividend of $0.17. This represents a $0.80 annualized dividend and a yield of 0.9%. iRadimed’s payout ratio is currently 45.71%.

Analyst Ratings Changes

IRMD has been the topic of several research reports. Weiss Ratings restated a “buy (b-)” rating on shares of iRadimed in a research note on Monday, December 29th. Freedom Capital upgraded iRadimed to a “strong-buy” rating in a research note on Thursday, April 2nd. Lake Street Capital restated a “buy” rating and set a $120.00 price objective on shares of iRadimed in a research note on Wednesday, February 11th. Finally, Roth Mkm restated a “buy” rating and set a $120.00 price objective on shares of iRadimed in a research note on Tuesday, February 10th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $120.00.

Institutional Trading of iRadimed

Institutional investors and hedge funds have recently bought and sold shares of the company. CWM LLC raised its position in shares of iRadimed by 19.5% during the 4th quarter. CWM LLC now owns 657 shares of the medical equipment provider’s stock worth $64,000 after purchasing an additional 107 shares during the period. Johnson Investment Counsel Inc. raised its position in shares of iRadimed by 0.7% during the 3rd quarter. Johnson Investment Counsel Inc. now owns 25,842 shares of the medical equipment provider’s stock worth $1,839,000 after purchasing an additional 187 shares during the period. Summit Global Investments raised its position in shares of iRadimed by 2.7% during the 3rd quarter. Summit Global Investments now owns 7,139 shares of the medical equipment provider’s stock worth $508,000 after purchasing an additional 188 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of iRadimed by 5.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,811 shares of the medical equipment provider’s stock worth $252,000 after purchasing an additional 234 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of iRadimed by 4.8% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,824 shares of the medical equipment provider’s stock worth $567,000 after purchasing an additional 267 shares during the period. Institutional investors and hedge funds own 92.34% of the company’s stock.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.